Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $132
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Overweight rating on Abbott Laboratories (NYSE:ABT) and raises the price target from $127 to $132.
July 24, 2023 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Abbott Laboratories and raises the price target from $127 to $132.
The raised price target by Barclays indicates a positive outlook for Abbott Laboratories. This could potentially lead to an increase in the stock price in the short term as it signals confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100